1. |
Siegel R L, Miller K D, Fedewa S A, et al. Colorectal cancer statistics, 2017. Ca A Cancer J Clin, 2017, 67(3): 177-193.
|
2. |
Long AG, Lundsmith ET, Hamilton KE. Inflammation and colorectal cancer. Curr Colorectal Cancer Rep, 2017, 13(4): 341-351.
|
3. |
Arnold M, Sierra MS, Laversanne M, et al. Global patterns and trends in colorectal cancer incidence and mortality. Gut, 2017, 66(4): 683-691.
|
4. |
Flemer B, Lynch DB, Brown J M R, et al. Tumour-associated and non-tumour-associated microbiota in colorectal cancer. Gut, 2017, 66(4): 633-643.
|
5. |
韩晶, 张雪, 张安度, 等. 肿瘤部位对根治性切除术后不同分期结直肠癌患者预后的影响. 中华外科杂志, 2018, 56(1): 68-73.
|
6. |
刘静, 李文雅, 曲秀娟, 等. 结直肠癌原发肿瘤部位对术后患者生存的影响. 中华结直肠疾病电子杂志, 2017, 6(4): 301-304.
|
7. |
Rice TW, Blackstone EH, Rusch VW. 7th Edition of the AJCC Cancer Staging Manual: , Esophagus and Esophagogastric Junction. Ann Surg Oncol, 2010, 17(7): 1721-1724.
|
8. |
Alexander J, Gildea L, Balog J, et al. A novel methodology for in vivo endoscopic phenotyping of colorectal cancer based on real-time analysis of the mucosal lipidome: a prospective observational study of the iknife. Surg Endosc, 2016, 31(3): 1361-1370.
|
9. |
祁清华, 王腾, 茆勇, 等. 癌结节对Ⅲ期结直肠癌患者预后判断的临床价值. 中华肿瘤杂志, 2016, 38(10): 784-789.
|
10. |
白洁, 刘兴华, 蔡明, 等. 腹腔镜异时性结直肠癌根治术的临床疗效. 中华普通外科杂志, 2017, 32(1): 9-11.
|
11. |
Zhu X, Fang X, Chen W, et al. Lower expression of platelet derived growth factor is associated with better overall survival rate of patients with idiopathic nonspecific interstitial pneumonia. J Thorac Dis, 2017, 9(3): 519-528.
|
12. |
胡俊杰, 熊治国. 左、右半结肠癌" 两种疾病论”的研究进展. 中华结直肠疾病电子杂志, 2016, 5(5): 380-385.
|
13. |
Liu F, Cong L, Jia H, et al. Is there a prognostic value of tumor location among Chinese patients with colorectal cancer? Oncotarget, 2017, 8(24): 38682-38692.
|
14. |
李聪, 王志敏, 赵江, 等. 结直肠癌不同发病部位的临床及分子特征差异. 中华预防医学杂志, 2014, 48(12): 1078-1082.
|
15. |
张卫刚, 张言言, 张宪文, 等. 不同分期结直肠癌患者的预后分析: 一项基于 SEER 数据库的回顾性研究. 中华结直肠疾病电子杂志, 2017, 6(1): 21-27.
|
16. |
Yang J, Du XL, Li ST, et al. Characteristics of differently located colorectal cancers support proximal and distal classification: A population-based study of 57 847 patients. Plos One, 2016, 11(12): e0167540.
|
17. |
Edita B, Ugnius M, Tadas Ž, et al. Significance of KRAS, NRAS, BRAF and PIK3CA mutations in metastatic colorectal cancer patients receiving Bevacizumab: a single institution experience. Acta Med Litu, 2016, 23(1): 24-34.
|
18. |
Sasaki Y, Hamaguchi T, Yamada Y, et al. Value of KRAS, BRAF, and PIK3CA mutations and survival benefit from systemic chemotherapy in colorectal peritoneal carcinomatosis. Asian Pac J Cancer Prev, 2016, 17(2): 539-543.
|
19. |
Nam SK, Yun S, Koh J, et al. BRAF, PIK3CA, and HER2 oncogenic alterations according to KRAS mutation status in advanced colorectal cancers with distant metastasis. Plos One, 2016, 11(3): e0151865.
|
20. |
Chien CW, Hou PC, Wu HC, et al. Targeting TYRO3 inhibits epithelial-mesenchymal transition and increases drug sensitivity in colon cancer. Oncogene, 2016, 35(45): 5872-5881.
|
21. |
Wang J, Mouradov D, Wang X, et al. Colorectal cancer cell line proteomes are representative of primary tumors and predict drug sensitivity. Gastroenterology, 2017, 153(4): 1082-1095.
|
22. |
Moradi-Marjaneh R, Khazaei M, Seifi S, et al. Pharmacogenetics of anticancer drug sensitivity and toxicity in colorectal cancer. Curr Pharm Des, 2018, 24(23): 2710-2718.
|
23. |
刘轩, 乔晓娟. 淋巴结转移度及 TNM 分期与结肠癌病人预后相关性分析. 内蒙古医科大学学报, 2017, 39(6): 550-552.
|
24. |
Knijn N, Mogk SC, Teerenstra S, et al. Perineural invasion is a strong prognostic factor in colorectal cancer: a systematic review. Am J Surg Pathol, 2016, 40(1): 103-112.
|
25. |
杨华, 肖刚, 吴国举. CEA 和 CA19-9 在结直肠癌患者中的诊断及预后价值. 中国现代普通外科进展, 2017, 20(7): 518-521.
|